Cited 15 times in
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김대준 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 김현기 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 문용화 | - |
dc.contributor.author | 박준철 | - |
dc.contributor.author | 백순명 | - |
dc.contributor.author | 신성관 | - |
dc.contributor.author | 이상길 | - |
dc.contributor.author | 이용찬 | - |
dc.contributor.author | 이창걸 | - |
dc.contributor.author | 정현수 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 표경호 | - |
dc.contributor.author | 허진 | - |
dc.date.accessioned | 2018-03-26T17:07:46Z | - |
dc.date.available | 2018-03-26T17:07:46Z | - |
dc.date.issued | 2015 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/157227 | - |
dc.description.abstract | The purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, whose diseases were not amenable to curative treatment and had progressed on platinum-based chemotherapy, were treated with dacomitinib 45 mg/day. The primary endpoint was objective response rate by RECISTv 1.1. Predictive biomarker analyses included the characterization of somatic mutations and gene expression using the Ion Torrent AmpliSeq Cancer Hotspot Panel and Nanostring nCounter, and investigation of their relationship with clinical outcomes. Of the 48 evaluable patients, 6 (12.5%) achieved partial responses and 29 (60.4%) had stable disease. The median response duration was 7.1 months. The median progression free survival (PFS) and overall survival (OS) was 3.3 months (95% CI, 2.4-4.3 months) and 6.4 months (95% CI, 4.4-8.4 months). Adverse events were mostly grade 1-2. Gene set enrichment analysis revealed that ERBB signaling pathway is significantly enriched in patients with PFS ≥ 4 months (n = 12) than PFS < 4 months (n = 21) (p < 0.001). Upregulation of ERBB signaling pathway was significantly associated with longer PFS (5.0 vs. 2.9 months, P = 0.016) and OS (10.0 vs. 4.8 months, P = 0.022). The most frequent mutations were TP53 (61%) followed by CDKN2A (8%), MLH1 (8%), FLT3 (8%) and EGFR (8%). Dacomitinib demonstrated clinical efficacy with manageable toxicity in platinum-failed R/M-ESCC. Screening of ERBB pathway-related gene expression profiles may help identify patients who are most likely benefit from dacomitinib. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Biomarkers, Tumor/antagonists & inhibitors | - |
dc.subject.MESH | Biomarkers, Tumor/genetics* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/genetics | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Carcinoma, Squamous Cell/pathology | - |
dc.subject.MESH | DNA Mutational Analysis | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Esophageal Neoplasms/drug therapy* | - |
dc.subject.MESH | Esophageal Neoplasms/genetics | - |
dc.subject.MESH | Esophageal Neoplasms/mortality | - |
dc.subject.MESH | Esophageal Neoplasms/pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Recurrence, Local* | - |
dc.subject.MESH | Patient Selection | - |
dc.subject.MESH | Precision Medicine | - |
dc.subject.MESH | Protein Kinase Inhibitors/adverse effects | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Quinazolinones/adverse effects | - |
dc.subject.MESH | Quinazolinones/therapeutic use* | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/antagonists & inhibitors | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/genetics | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Thoracic & Cardiovascular Surgery | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Sung-Moo Kim | - |
dc.contributor.googleauthor | Hyunki Kim | - |
dc.contributor.googleauthor | Kyoung-Ho Pyo | - |
dc.contributor.googleauthor | Jong-Mu Sun | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Nak-Jung Kwon | - |
dc.contributor.googleauthor | Hwan Jung Yun | - |
dc.contributor.googleauthor | Hoon-Gu Kim | - |
dc.contributor.googleauthor | Ik-Joo Chung | - |
dc.contributor.googleauthor | Jong Seok Lee | - |
dc.contributor.googleauthor | Kyung Hee Lee | - |
dc.contributor.googleauthor | Dae Joon Kim | - |
dc.contributor.googleauthor | Chang‑Geol Lee | - |
dc.contributor.googleauthor | Jin Hur | - |
dc.contributor.googleauthor | Hyunsoo Chung | - |
dc.contributor.googleauthor | Jun Chul Park | - |
dc.contributor.googleauthor | Sung Kwan Shin | - |
dc.contributor.googleauthor | Sang Kil Lee | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Yong Wha Moon | - |
dc.contributor.googleauthor | Yong Chan Lee | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Soonmyung Paik | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.18632/oncotarget.6056 | - |
dc.contributor.localId | A00368 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01108 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01370 | - |
dc.contributor.localId | A01676 | - |
dc.contributor.localId | A01823 | - |
dc.contributor.localId | A02112 | - |
dc.contributor.localId | A02812 | - |
dc.contributor.localId | A02988 | - |
dc.contributor.localId | A03240 | - |
dc.contributor.localId | A03765 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04809 | - |
dc.contributor.localId | A04370 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 26462025 | - |
dc.subject.keyword | biomarker | - |
dc.subject.keyword | epidermal growth factor receptor | - |
dc.subject.keyword | esophageal squamous cell carcinoma | - |
dc.subject.keyword | tyrosine kinase inhibitor | - |
dc.contributor.alternativeName | Kim, Dae Joon | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Kim, Hyun Ki | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Moon, Yong Wha | - |
dc.contributor.alternativeName | Park, Jun Chul | - |
dc.contributor.alternativeName | Paik, Soon Myung | - |
dc.contributor.alternativeName | Shin, Sung Kwan | - |
dc.contributor.alternativeName | Lee, Sang Kil | - |
dc.contributor.alternativeName | Lee, Yong Chan | - |
dc.contributor.alternativeName | Lee, Chang Geol | - |
dc.contributor.alternativeName | Chung, Hyun Soo | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Pyo, Kyoung Ho | - |
dc.contributor.alternativeName | Hur, Jin | - |
dc.contributor.affiliatedAuthor | Kim, Dae Joon | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Ki | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Moon, Yong Wha | - |
dc.contributor.affiliatedAuthor | Park, Jun Chul | - |
dc.contributor.affiliatedAuthor | Paik, Soon Myung | - |
dc.contributor.affiliatedAuthor | Shin, Sung Kwan | - |
dc.contributor.affiliatedAuthor | Lee, Sang Kil | - |
dc.contributor.affiliatedAuthor | Lee, Yong Chan | - |
dc.contributor.affiliatedAuthor | Lee, Chang Geol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Soo | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Pyo, Kyoung Ho | - |
dc.contributor.affiliatedAuthor | Hur, Jin | - |
dc.citation.volume | 6 | - |
dc.citation.number | 42 | - |
dc.citation.startPage | 44971 | - |
dc.citation.endPage | 44984 | - |
dc.identifier.bibliographicCitation | ONCOTARGET , Vol.6(42) : 44971-44984, 2015 | - |
dc.identifier.rimsid | 41787 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.